Ken Griffin Cytom X Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,900 shares of CTMX stock, worth $10,858. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,900
Previous 19,500
54.36%
Holding current value
$10,858
Previous $30,000
36.67%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding CTMX
# of Institutions
89Shares Held
43.9MCall Options Held
105KPut Options Held
4.5K-
Bvf Inc San Francisco, CA6.6MShares$8.05 Million0.43% of portfolio
-
Tang Capital Management LLC San Diego, CA6.45MShares$7.87 Million1.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.86MShares$5.93 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$4.32 Million0.17% of portfolio
-
Acadian Asset Management LLC Boston, MA2.69MShares$3.28 Million0.02% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $80.5M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...